| FIA | fistula in ano; fluorescent immunoassay; focal immunoassay; Freund incomplete adjuvant |
|---|---|
| CPBA | Competitive Protein Binding Assay |
| AOO | anodal opening odor; atrial asynchronous (competitive, fixed-rate) [pacemaker] |
| CBPA | competitive protein-binding assay |
| CISH | competitive in situ hybridization |
| C-ELISA | Competitive ELISA |
|---|---|
| cPCR | Competitive PCR |
| C-ELISA | Competitive enzyme-linked immunosorbent assay |
| CE | Competitive exclusion |
| cPCR | Competitive polymerase chain reaction |
| competitive antagonist | An antimetabolite. (05 Mar 2000) |
|---|---|
| competitive behaviour | The direct struggle between individuals for environmental necessities or for a common goal. (12 Dec 1998) |
| competitive bidding | Pricing statements presented by more than one party for the purpose of securing a contract. (12 Dec 1998) |
| competitive binding assay | General term for an assay in which a binder competes for labelled versus unlabelled ligand; following separation of free and bound ligand, the ligand (the analyte assayed) is quantitated by relating bound and unbound ratios to known standards. See: enzyme-linked immunosorbent assay, radioreceptor assay, immunoassay, enzyme-multiplied immunoassay technique, radioimmunoassay. Synonym: displacement analysis, saturation analysis. (05 Mar 2000) |
| competitive inhibition | <chemistry> Inhibitor that occupies the active site of an enzyme or the binding site of a receptor and prevents the normal substrate or ligand from binding. at sufficiently high concentration of the normal ligand inhibition is lost: the Km is altered by the competitive inhibitor, but the Vmax remains the same. (05 Jan 1998) |
| competitive medical plans | Alternative health care delivery mechanisms, such as preferred provider organizations or other health insurance services or prepaid plans (other than health maintenance organizations), that meet medicare qualifications for a risk-sharing contract. (12 Dec 1998) |
| microparticle enzyme immunoassay | A technique in which the solid-phase support consists of very small microparticles in liquid suspension. Specific reagent antibodies are covalently bound to the microparticles. Antigen, if present, is then "sandwiched" between bound antibodies and antigen-specific, enzyme-labelled antibodies. Antigen-antibody complexes are detected and quantitated by analysis of fluorescence from the enzyme-substrate interaction. Acronym: MEIA (05 Mar 2000) |
| solid phase immunoassay | Immunoassay in which the antigen or serum is bound to a solid surface, such as a microplate wall or the sides of a tube, the other reactants being free in solution. (05 Mar 2000) |
| double antibody immunoassay | A method of separating antibody-bound antigen (e.g., insulin) from free antigen by precipitating the former with antibody specific for immunoglobulin. Synonym: double antibody immunoassay, double antibody method. (05 Mar 2000) |
| immunoassay | <investigation> A process that measures and identifies a specific biological substance such as an antigen. (09 Oct 1997) |
| thin-layer immunoassay | A method for detection of antigen-antibody reactions, applicable to detection of either antigen or antibody, based on the fact that either reactant, when added to a polystyrene surface (such as a well in a polystyrene plate) is adsorbed as a thin layer and acts as an immunosorbent capable of binding with the second reactant. (05 Mar 2000) |
| enzyme immunoassay | The general term for an expanding technical arsenal of testing which allows a full range of quantitative analyses for both antigen and antibodies. These tests use colour-changed products of enzyme-substrate interaction (or inhibition) to measure the antigen-antibody reaction. Examples of EIA procedures (EMIT, ELISA, MAC, MEIA) follow. Acronym: EIA (05 Mar 2000) |
| enzyme-multiplied immunoassay technique | A type of immunoassay in which the ligand is labelled with an enzyme, and the enzyme-ligand-antibody complex is enzymatically inactive, allowing quantitation of unlabelled ligand. The test uses antibodies that react only with the particular drug for which the sample is being tested. The antibodies attach themselves to the drug if it is present in the sample. It is not designed to measure amounts of the drug present, only to detect its presence or absence. It is used predominantly, but not exclusively, for the detection of drugs of abuse in the urine. See: competitive binding assay, enzyme-linked immunosorbent assay. (05 Mar 2000) |
| fluorescence immunoassay | <technique> A sensitive technique which uses fluorescein, a fluorescent molecule, to measure the antigen or antibody concentration in a solution. (09 Oct 1997) |
| fluorescence polarisation immunoassay | A technique which takes advantage of the increased polarisation (non-random propagation of emission) of fluorescent light emissions when a fluorescent labelled antigen is bound by reagent antibody. The higher the concentration of unlabelled patient antigen present in the test mixture, the less bound fluorescent antigen is present and, consequently, the lower the polarisation of the fluorescent light emission. Standard calibration yields quantitative results. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|